Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art

Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art

Multiple myeloma (MM) is the most common indication for autologous stem cell transplantation (ASCT), and outpatient models have been widely developed in this setting. Although numerous studies have demonstrated the safety and feasibility of outpatient ASCT, it is not a routine procedure. Stringent g...

Full description

Bibliographic Details
Main Authors: Massimo Martino, Annalisa Paviglianiti, Mara Memoli, Giovanni Martinelli, Claudio Cerchione
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
multiple myeloma
autologous stem cell transplantation
outpatient
inpatient
novel agents
cost-effectiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.592487/full
id doaj-6f674bb0eb09467a82e8520f758d7c3d
record_format Article
spelling doaj-6f674bb0eb09467a82e8520f758d7c3d2020-11-25T03:59:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-11-011010.3389/fonc.2020.592487592487Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-ArtMassimo Martino0Annalisa Paviglianiti1Mara Memoli2Mara Memoli3Giovanni Martinelli4Claudio Cerchione5Stem Cell Transplant Program, Clinical Section, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, ItalyStem Cell Transplant Program, Clinical Section, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, ItalyDepartment of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, FranceDepartment of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, ItalyHematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ItalyHematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ItalyMultiple myeloma (MM) is the most common indication for autologous stem cell transplantation (ASCT), and outpatient models have been widely developed in this setting. Although numerous studies have demonstrated the safety and feasibility of outpatient ASCT, it is not a routine procedure. Stringent guidelines for patient selection and clinical management, including functional status, caregiver support, and psychological aspects, are essential to identify eligible patients. However, there is still no general agreement on these criteria. Quality of life data are limited and contradictory. There is considerable variability in outpatient transplant models, and there are no randomised studies supporting the use of one over the other. Studies evaluating results in terms of long-term survival, transplant toxicity in comparison with a standard approach are lacking. The procedure is cost-effective within the context of a hospital budget, but an in-depth analysis of the real cost of these programmes has yet to be performed.https://www.frontiersin.org/articles/10.3389/fonc.2020.592487/fullmultiple myelomaautologous stem cell transplantationoutpatientinpatientnovel agentscost-effectiveness
collection DOAJ
language English
format Article
sources DOAJ
author Massimo Martino
Annalisa Paviglianiti
Mara Memoli
Mara Memoli
Giovanni Martinelli
Claudio Cerchione
spellingShingle Massimo Martino
Annalisa Paviglianiti
Mara Memoli
Mara Memoli
Giovanni Martinelli
Claudio Cerchione
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
Frontiers in Oncology
multiple myeloma
autologous stem cell transplantation
outpatient
inpatient
novel agents
cost-effectiveness
author_facet Massimo Martino
Annalisa Paviglianiti
Mara Memoli
Mara Memoli
Giovanni Martinelli
Claudio Cerchione
author_sort Massimo Martino
title Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
title_short Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
title_full Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
title_fullStr Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
title_full_unstemmed Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
title_sort multiple myeloma outpatient transplant program in the era of novel agents: state-of-the-art
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2020-11-01
description Multiple myeloma (MM) is the most common indication for autologous stem cell transplantation (ASCT), and outpatient models have been widely developed in this setting. Although numerous studies have demonstrated the safety and feasibility of outpatient ASCT, it is not a routine procedure. Stringent guidelines for patient selection and clinical management, including functional status, caregiver support, and psychological aspects, are essential to identify eligible patients. However, there is still no general agreement on these criteria. Quality of life data are limited and contradictory. There is considerable variability in outpatient transplant models, and there are no randomised studies supporting the use of one over the other. Studies evaluating results in terms of long-term survival, transplant toxicity in comparison with a standard approach are lacking. The procedure is cost-effective within the context of a hospital budget, but an in-depth analysis of the real cost of these programmes has yet to be performed.
topic multiple myeloma
autologous stem cell transplantation
outpatient
inpatient
novel agents
cost-effectiveness
url https://www.frontiersin.org/articles/10.3389/fonc.2020.592487/full
work_keys_str_mv AT massimomartino multiplemyelomaoutpatienttransplantprogramintheeraofnovelagentsstateoftheart
AT annalisapaviglianiti multiplemyelomaoutpatienttransplantprogramintheeraofnovelagentsstateoftheart
AT maramemoli multiplemyelomaoutpatienttransplantprogramintheeraofnovelagentsstateoftheart
AT maramemoli multiplemyelomaoutpatienttransplantprogramintheeraofnovelagentsstateoftheart
AT giovannimartinelli multiplemyelomaoutpatienttransplantprogramintheeraofnovelagentsstateoftheart
AT claudiocerchione multiplemyelomaoutpatienttransplantprogramintheeraofnovelagentsstateoftheart
_version_ 1724455402352934912

Similar Items